Protective effect of oxymatrine on chronic rat heart failure

Table 2 Assessment of cardiac function in different groups

	Sham	HF	OMT (L)	OMT (M)	OMT (H)
Number	12	12	12	12	12
BW (g)	218.2 ± 12.7	227.1 ± 11.1	220.5 ± 23.5	232.4 ± 17.3	236.6 ± 15.4
HW/BW (mg/g)	2.42 ± 0.27	4.39 ± 0.19**	4.16 ± 0.33	3.11 ± 0.28^Δ	3.08 ± 0.15^Δ
HR (beats/min)	427 ± 15	435 ± 19	418 ± 28	427 ± 26	419 ± 17
LVEDP (mmHg)	3.9 ± 1.3	8.2 ± 1.8**	7.9 ± 1.2	5.1 ± 1.5^ΔΔ	4.6 ± 1.1^ΔΔ
dp/dt _max (mmHg/s)	4,182.77 ± 209. 53	2,462.95 ± 218.13**	2,783.74 ± 251.12	3,794.17 ± 223.59^ΔΔ	3,815.57 ± 205.11^ΔΔ
dp/dt _min (mmHg/s)	−2,892.31 ± 245.17	−1,554.46 ± 174.68**	−1,668.62 ± 171.53	−2,515.71 ± 188.43^ΔΔ	−2,661.78 ± 202.42^ΔΔ

MI myocardial infarction, BW body weight, HW heart weight, HR heart rate, LVEDP left ventricular end-diastolic pressure, dp/dt_max maximum change in systolic pressure over time, dp/dt_min maximum change in the rate of relaxation over time. Data are presented as mean ± SE 1 mmHg = 0.133 kPa, ** P < 0.01 HF versus sham, * P < 0.05 HF versus sham, ^ΔΔ P < 0.01 medium-dose, high-dose versus HF, ^Δ P < 0.05 medium-dose, high-dose versus HF

ISSN: 1880-6562